Afrezza Market Report 2026

Afrezza Market Overview

• The Afrezza market growth in the historic period has been driven by increasing diabetes prevalence, limitations of injectable insulin • Market expansion is supported by rising type 2 diabetes population, growing acceptance of inhalation drug delivery • Growth Driver: Rising Diabetes Prevalence Fuels Growth In The Afrezza Market • Market Trend: Industry Focus On Improving Afrezza For Type 1 Diabetes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Afrezza Market?

Afrezza is an inhaled insulin medication used to control blood sugar levels in people with diabetes. It is a rapid-acting form of insulin that is absorbed quickly through the lungs, offering a fast-acting alternative to injectable insulin. Afrezza is typically used to manage blood sugar spikes that occur after meals (postprandial blood sugar). The main indication types of afrezza are type 1 diabetes and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition in which the immune system attacks the insulin-producing beta cells in the pancreas, leading to little or no insulin production. The distribution channels are hospitals and clinics, retail pharmacies, and specialty pharmacies, and the end users are adult patients and geriatric patients.

What Is The Afrezza Market Growth Forecast?

The growth in the forecast period can be attributed to rising type 2 diabetes population, growing acceptance of inhalation drug delivery, expansion into broader patient groups, improvements in pulmonary safety data, increased physician awareness. Major trends in the forecast period include growing adoption of inhaled insulin therapies, rising preference for needle-free diabetes management, increased focus on postprandial glucose control, expansion of rapid-acting insulin alternatives, improved patient adherence through convenience.

What Are The Drivers Of The Afrezza Market?

The increase in the prevalence of diabetes is expected to propel the growth of the afrezza market going forward. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels resulting from insufficient insulin production, impaired insulin action, or both. Diabetes is rising due to increasing rates of obesity, sedentary lifestyles, unhealthy diets, an aging population, urbanization, genetic predisposition, and greater awareness and diagnosis of the condition. Afrezza is essential for diabetes treatment as it quickly controls post-meal blood sugar spikes, preventing complications and ensuring effective glucose management. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in March 2023, the percentage of people with type 1 diabetes in England receiving 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% in 2022. Therefore, the increase in the prevalence of diabetes drives the afrezza industry. The rise in healthcare expenditure is expected to propel the growth of the afrezza market going forward. Healthcare expenditure refers to the total amount of financial resources spent on medical services, healthcare infrastructure, pharmaceuticals, and healthcare-related activities. Healthcare expenditure is rising due to factors such as an aging population, increasing prevalence of chronic and lifestyle-related diseases, advances in medical technology, and greater access to healthcare services. Healthcare expenditure for Afrezza, an inhaled insulin therapy, focuses on the cost of treatment, including medication, administration devices, and ongoing monitoring, aiming to improve diabetes management efficiency. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the increase in healthcare expenditure drives the afrezza industry.

Key Players In The Global Afrezza Market

Major companies operating in the afrezza market are Mannkind Corporation

Global Afrezza Market Trends and Insights

Major companies operating in the Afrezza market are focusing on developing technically advanced products by carrying out detailed studies regarding the product and diabetes. Afrezza is used to control Type 1 Diabetes using insulin inhalers. For instance, in June 2023, MannKind Corporation, a US-based biopharmaceutical company, initiated the INHALE-3 study, a clinical trial designed to address a key unmet need for adults with Type 1 Diabetes. The trial spans 17 weeks and includes a 13-week extension phase, allowing researchers to further evaluate outcomes over an extended period. INHALE-3 is a randomized, controlled study aimed at assessing innovative treatment approaches that could improve daily disease management and overall patient well-being. By launching this trial, MannKind seeks to generate meaningful clinical insights that may support more effective therapeutic options for individuals living with Type 1 Diabetes.

What Defines the Afrezza Market?

The afrezza market consists of sales of inhaled insulin cartridges and inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Afrezza Market Report 2026?

The afrezza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the afrezza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.